Compared to the pace of innovation in electronic consumer products, the pace of innovation in electronic medical devices is lagging behind. It is the overarching objective of Moore4Medical to accelerate innovation in electronic medical devices. Moore4Medical will:

  • Address emerging medical domains
    The convergence between the Pharmaceutical, MedTech and ECS industries, is resulting in new exciting new opportunities for industry and society that will help managing the cost of healthcare.

  • Develop open and enabling technology platforms
    To help the emerging applications and technologies bridge “the Valley of Death” in shorter time and at lower cost.
  • Ensure European leadership
    Open technology platforms that will reduce fragmentation and avoid point solutions will be essential factors in ensuring a sustainable and affordable healthcare in an aging population.

Emerging medical domains

We live in an ara where the borders between, Pharma, MedTech and the Electronic Components and Systems industry (ECS) are fading. At the intersection between these domains new opportunities are emerging that offer great opportunities for industry, as well as for society:

Implantable devices

Small implantable devices “Bioelectronic Medicines” implanted on nerves leading to organs will be used to treat a variety of diseases, especially in the field of chronic autoimmune diseases.

Organ-on-chip

Organ-on-chips, mimicking the basic functions of organs will be used to develop (personalized) medicines, test new drugs for safety, and reduce animal testing.

Drug adherence

Miniature sensors and micropumps will ensure that expensive (biological) drugs can be administered in the home environment in the correct and safe way.

Next generation ultrasound

3D Ultrasound imaging based on MEMS ultrasound transducers in combination with AI algorithms brings ultrasound diagnostics out of the hospital to semiprofessionals, rural and remote areas, and even consumers.

Towards X-ray free surgery

Advanced optical tracking techniques and optical shape sensing will practically eliminate the need for ionizing X-ray imaging during (minimally invasive) interventions.

Continuous monitoring

Wearable sensors and remote sensing technologies will reduce hospitalization, resulting in more comfort for the patient and less costly clinical trials in drug development.

© Copyright | Moore4Medical